Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Study of Osimertinib in Combination With Gefitinib in EGFR Inhibitor naive Advanced EGFR Mutant Lung Cancer

Next Previous
Trial Profile

A Phase 1/2 Study of Osimertinib in Combination With Gefitinib in EGFR Inhibitor naive Advanced EGFR Mutant Lung Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 23 Jan 2019

At a glance

  • Drugs Gefitinib (Primary) ; Osimertinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 14 Jan 2019 Study design has been changed from Parallel Assignment to Single Group Assignment and number of treatment arms decreased.
    • 31 Aug 2018 Biomarkers information updated
    • 10 Aug 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top